Drugs / dnaJ peptide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00000435 Comparator | Sep 1999 → Sep 2004 | rheumatoid arthritis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dnaJ peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000435 ↗ |
| Route | Oral | “They received oral doses of 25 mg of dnaJP1 or placebo daily for 6 months.” PMID 19877047 ↗ Nov 2009 |